JPRN-UMIN000038522已完成未知
Evaluation of the Clinician Collaboration ACP Model Utilizing the Serious Illness Conversation Guide (SICG) in Outpatient Oncology Clinic - Evaluation of the ACP model in Outpatient Oncology Clinic
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 61
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Excluded when any of the following items apply. 1) Patients with the Distress and Impediment Thermometer (DIT) test score of 4 or more for distress and a score of 3 or more for impediment. 2) Patients who have had an ACP discussion prior to participation in this study, covering the full range of medical condition awareness, prognostic information sharing, values identification, and discussion of desired medical care and care. 3) Patients with higher brain dysfunction (apparent intellectual decline, attention deficits, and dysgraphia). 4) Patients who are unable to speak, read, or write in Japanese. 5) Patients who are judged by the attending physician to be unsuitable to be included in this study.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 20.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2015-005317-68-BEAcerta Pharma, BV60
进行中（未招募）
1 期
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2015-005317-68-GBAcerta Pharma B.V.60
进行中（未招募）
1 期
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 19.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2015-005317-68-ESAcerta Pharma, BV80
进行中（未招募）
1 期
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 19.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2015-005317-68-FRAcerta Pharma, BV80
已完成
不适用
A Study of Collaborative Treatment between Medical Professionals and Lawyers in Hospitalization for Assessment in the Act of Medical Treatment and Supervision: Phase 1All mental disordersJPRN-UMIN000051230Chiba University143